Athithi
AlzeCure Pharma has found a partner for its Alzheimer’s program, and the numbers attached to the deal are eye-catching, though not all of them in the way the headline suggests. The Swedish biotech said on July 1 that it has signed an out-licensing and collaboration agreement with QuantumCell, a Danish “tech-enabled” biotech, handing over global … Read more
Boulevard Bio is paying $20 million upfront and committing up to $1.6 billion in milestones for the global rights to MTS-128, a trispecific T-cell engager.
NeuroPulse — Wk 26 · 2026 · Synopulse NeuroPulseDeep pine banner. An indigo neural network of neurons and synapses fills the right side, with a gold signal pulse firing along a chain of neurons, beside the NeuroPulse wordmark under the Synopulse and The Pulse kicker. Synopulse · The Pulse NeuroPulse This week in neuroscience Week … Read more
The rules of pharmaceutical market access are being rewritten. From IRA-mandated price ceilings to AI-driven outcomes contracting.
Pfizer has signed one of the year’s largest cross-Pacific oncology deals, pledging $650 million upfront and up to $9.85 billion in milestones to co-develop 12 early-stage cancer assets with China’s Innovent Biologics.
The antibody–drug conjugate field arrives at ASCO 2026 in a fundamentally different shape. This Synopulse pre-conference briefing maps the five catalysts, 16+ assets, and strategic themes that will reshape the competitive landscape.
NICE has recommended routine NHS access to nusinersen and risdiplam for spinal muscular atrophy.
The UK health watchdog National Institute for Health and Care Excellence (NICE) has recommended a suite of digital platforms to help people with asthma better manage their condition, signalling growing confidence in app-based tools as part of routine care, while stopping short of full endorsement pending further evidence. In draft guidance published yesterday, NICE said … Read more
Last week’s policy signals from Germany underscored a clear regulatory theme: access increasingly hinges on comparative evidence, not just innovation or unmet need. New assessments from the Institute for Quality and Efficiency in Health Care (IQWiG) highlighted where evidence is strong enough to support added benefit, where gaps remain despite growing treatment options. Multiple myeloma: … Read more
CMS confirms Medicare coverage for MTF Biologics’ AmnioBand Membrane and AlloPatch Pliable under updated LCDs for diabetic foot and venous leg ulcers starting 2026.